drugset
drugset / Trial / NCT01839929

A Study to Assess the Safety and Efficacy of ADVAGRAF (Tacrolimus Modified Release Formulation) in Kidney Transplant Patients Who Were Treated With PROGRAF

NCT01839929 ↗

Phase 4 Completed 138 enrolled Astellas Pharma Inc
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy of tacrolimus modified release formulation Advagraf® after conversion from Prograf® in stable kidney transplant patients.

Timeline

Start
2010-09
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule — Oral
Subject Tacrolimus Small molecule — Oral

Indications

No indication recorded.